Read the Beforeitsnews.com story here. Advertise at Before It's News here.
Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views
Now:
Last hour:
Last 24 hours:
Total:

MindMed launches Phase 1 study of potential LSD 'emergency off-switch' ketanserin

% of readers think this story is Fact. Add your two cents.


Mind Medicine (MindMed) Inc (NEO:MMED) (OTCQB:MMEDF) (FRA:MMQ) announced Wednesday the start of a Phase 1 study for its LSD neutralizer technology, which is designed to shorten and stop the effects of an LSD trip during a therapy session.  

LSD is thought to induce its prototypical psychedelic effects primarily by stimulating the serotonin 5-HT2A receptor. Studies of healthy volunteers have shown that administering ketanserin, a 5-HT2A receptor antagonist, before administering LSD almost completely, prevents the psychedelic drug’s acute effects.  

This LSD neutralizer study is designed to find out if this same result can be achieved when administering ketanserin to patients after they have received LSD, once the psychedelic effects have fully established.

READ: MindMed strikes partnership with Swiss startup MindShift Compounds to develop and patent next-gen psychedelic compounds

The study hypothesis is that ketanserin (40mg), administered to healthy volunteers one hour after taking LSD, significantly shortens and reduces the acute subjective effects of the LSD (100μg) compared to LSD alone, followed by a placebo. Such a finding would confirm a previous in vivo result and indicate that LSD produces its psychedelic effects only when present at the receptor and that the LSD-receptor interaction can be reversed pharmacologically and relatively rapidly. 

MindMed is working in collaboration with University Hospital Basel’s Liechti Lab on the clinical trial evaluating the effect of ketanserin on the acute response to LSD in healthy subjects after LSD administration. The study is expected to be completed by the end of the year, the company said. 

“Based on preclinical and ongoing clinical research, we expect highly relevant results from this proof of concept study in healthy subjects,” University Hospital Basel leader Matthias Liechti said in a statement. “If working as expected and fully developed, the approach would allow treatment of patients with LSD while having an option to end an experience if considered necessary by the patient or therapist. Such a technique will further increase the safety of using LSD in a therapeutic setting and will provide a tool for reducing and ending psychedelic experiences induced by LSD or possibly other psychedelics.”

Ketanserin was originally discovered at Janssen Pharmaceuticals in 1980 and has been actively marketed as an antihypertensive agent, the company said. This study will support the patent application that was filed last year, preserving all worldwide rights for a neutralizer technology intended to shorten and stop the effects of an LSD trip during a therapy session.

“One of the many fears and stigmas associated with psychedelics are rare happenings of bad trips,” MindMed Executive President Miri Halperin Wernli said. “We are seeking to equip therapists and other medical professionals with the resources and technology to better control the effects of dosing LSD, and other 5-HT2A agonists such as psilocybin, in a clinical setting to improve the patient experience and outcomes.”

The company is also developing LSD-assisted therapies through its Project Lucy program, and its plans include a Phase 2b trial for anxiety disorders planned to be conducted fully through the FDA pathway. Because of the emphasis on LSD, MindMed is working to make its experiential therapies most suitable for a therapeutic setting and thereby create the best possible patient experience, the company said.

That is why ketanserin, which may act as a sort of emergency off switch for psychedelic-assisted therapies, could prove crucial when further developed. 

“This advancement could pave the way for greater therapeutic applications of LSD to really allow our brain to reach states of complexity beyond that which it has ever experienced in normal daily life,” Halperin Wernli said. “We believe that this technology, when further developed, could in the future be marketed as an added feature to shorten a therapy session and stop a session if it is so chosen by the patient or the therapist. With this additional potential freedom to operate known to the patient, it may enable the brain to function in a way beyond what anatomy usually allows.”

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Story by ProactiveInvestors



Source: http://www.proactiveinvestors.com/companies/news/941580/mindmed-launches-phase-1-study-of-potential-lsd--emergency-off-switch--ketanserin-941580.html


Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world.

Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.

"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.

Please Help Support BeforeitsNews by trying our Natural Health Products below!


Order by Phone at 888-809-8385 or online at https://mitocopper.com M - F 9am to 5pm EST


Order by Phone at 888-809-8385 or online at https://www.herbanomic.com M - F 9am to 5pm EST


Humic & Fulvic Trace Minerals Complex - Nature's most important supplement! Vivid Dreams again!

HNEX HydroNano EXtracellular Water - Improve immune system health and reduce inflammation

Ultimate Clinical Potency Curcumin - Natural pain relief, reduce inflammation and so much more.

MitoCopper - Bioavailable Copper destroys pathogens and gives you more energy. (See Blood Video)
Oxy Powder - Natural Colon Cleanser!  Cleans out toxic buildup with oxygen! 
Nascent Iodine - Promotes detoxification, mental focus and thyroid health.
Smart Meter Cover -  Reduces Smart Meter radiation by 96%!  (See Video)

Immusist Beverage Concentrate - Proprietary blend, formulated to reduce inflammation while hydrating and oxygenating the cells.

Report abuse
Loading...

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

MOST RECENT
Load more ...

SignUp

Login

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.